US3638649A - Implantable prosthetic pass-through device - Google Patents

Implantable prosthetic pass-through device Download PDF

Info

Publication number
US3638649A
US3638649A US839297A US3638649DA US3638649A US 3638649 A US3638649 A US 3638649A US 839297 A US839297 A US 839297A US 3638649D A US3638649D A US 3638649DA US 3638649 A US3638649 A US 3638649A
Authority
US
United States
Prior art keywords
segments
cannula
distal
skin
roughened
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US839297A
Inventor
Robert A Ersek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NEUROMEDICS Inc A CORP OF TX
University of Minnesota
Original Assignee
University of Minnesota
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Minnesota filed Critical University of Minnesota
Application granted granted Critical
Publication of US3638649A publication Critical patent/US3638649A/en
Assigned to NEUROMEDICS, INC., A CORP. OF TX reassignment NEUROMEDICS, INC., A CORP. OF TX ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: MED GENERAL, INC.,
Assigned to CHASE MANHATTAN BANK, N.A., THE, BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION,, FIRST FREEPORT NATIONAL BANK, FIRST NATIONAL BANK OF CHICAGO, THE, TRUST COMPANY BANK, BRAZOSPORT BANK OF TEXAS, CITIBANK, N.A., AS AGENT reassignment CHASE MANHATTAN BANK, N.A., THE SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). SUBECT TO CONDITIONS INVOLVING SAID PATENTS IN SCHEDULE II (SEE DOCUMENT FOR DETAILS) Assignors: AMERICAN PACEMAKER CORPORATION, CALCITEK, INC., INTERMEDICS CARDIASSIST, INC., INTERMEDICS INTRAOCULAR, INC., INTERMEDICS, INC., INTERVASCULAR, INC., MASTER IMAGES, INC., NEUROMEDICS, INC., SURGITRONICS CORPORATION
Assigned to CITICORP MILTILEASE (SEF), INC. reassignment CITICORP MILTILEASE (SEF), INC. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMERICAN PACEMAKER CORPORATON, A CORP. OF MA., CALCITEK, INC., A CORP. OF TEXAS, CARBOMEDICS, INC., A CORP. OF TEXAS, INTERMEDICS CARDIASSIST, INC., INTERMEDICS INTRAOCULAR, INC., A CORP. OF TEXAS, INTERMEDICS, INC., NEUROMEDICS, INC., SURGITRONICS CORPORATION, A CORP. OF TEXAS
Assigned to CITIBANK, N.A. reassignment CITIBANK, N.A. SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMERICAN PACEMAKER CORPORATION A MA CORP., CALCITEK, INC., A TX CORP., CARBOMEDICS, INC., A TX CORP., INTERMEDICS CARDIASSIST, INC., A TX CORP., INTERMEDICS INTRAOCULAR, INC., A TX CORP., INTERMEDICS, INC., A TX CORP, NEUROMEDICS, INC., A TX CORP, SURGITRONICS CORPORATION A TX CORP.
Assigned to B.A. LEASING CORPORATION reassignment B.A. LEASING CORPORATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMERICAN PACEMAKER CORPORATION, A CORP. OF MA., CALCITEK, INC., CARBOMEDICS, INC.,, INTERMEDICS CARDIASSIST, INC., INTERMEDICS INTRAOCULAR, INC., A CORP. OF TEXAS, INTERMEDICS, INC., A CORP. OF TEXAS, NEUROMEDICS, INC., A CORP. OF TEXAS, SURGITRONICS CORPORATION, A CORP. OF TEXAS
Assigned to CHASE COMMERCIAL CORPORATION reassignment CHASE COMMERCIAL CORPORATION SECURITY INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AMERICAN PACEMAKER CORPORATION, A CORP. OF MA., CALCITEK, INC., A CORP. OF TEXAS, CARBOMEDICS, INC., INTERMEDICS CARDIASSIST, INC., A CORP OF TX., INTERMEDICS INTRAOCULAR, INC., A CORP. OF TEXAS, INTERMEDICS, INC., A CORP. OF TEXAS, NEUROMEDICS INC., A CORP. OF TEXAS, SURGITRONICS CORPORATION, A CORP. OF TEXAS
Assigned to INTERMEDICS, INC., INTERMEDICS CARDIASSIST, INC., INTERMEDICS INTRAOCULAR, INC., SURGITRONICS CORPORATION, CARBOMEDICS, INC., NEUROMEDICS, INC., CALCITEK, INC., TEXAS CORPORATION AND AMERICAN PACEMAKER CORPORATION, A CORP OF MASS. reassignment INTERMEDICS, INC., INTERMEDICS CARDIASSIST, INC., INTERMEDICS INTRAOCULAR, INC., SURGITRONICS CORPORATION, CARBOMEDICS, INC., NEUROMEDICS, INC., CALCITEK, INC., TEXAS CORPORATION AND AMERICAN PACEMAKER CORPORATION, A CORP OF MASS. SECURED PARTY HEREBY RELEASE THE SECURITY INTEREST IN AGREEMENT RECORDED AUGUST 5, 1985. REEL 4434 FRAMES 728-782 Assignors: CITIBANK, N.A.
Assigned to INTERMEDICS, INC., INTERMEDICS CARDIASSIST, INC., INTERMEDICS INTRAOCULAR, INC., SURGITRONICS CORPORATION, CARBOMEDICS, INC., NEUROMEDICS, INC., CALCITEK, INC., INTERVASCULAR, INC., AND MASTER IMAGES, INC., TEXAS CORPORATIONS, AND AMERICANPACEMAKER CORPORATION, A CORP. OF MA. reassignment INTERMEDICS, INC., INTERMEDICS CARDIASSIST, INC., INTERMEDICS INTRAOCULAR, INC., SURGITRONICS CORPORATION, CARBOMEDICS, INC., NEUROMEDICS, INC., CALCITEK, INC., INTERVASCULAR, INC., AND MASTER IMAGES, INC., TEXAS CORPORATIONS, AND AMERICANPACEMAKER CORPORATION, A CORP. OF MA. SAID PARTIES RECITES OBLIGATIONS RECITED IN SECURITY AGREEMENT RECORDED SEPTEMBER 17, 1984 REEL 4303 FRAMES 077-127 HAVE BEEN PAID IN FULL ALL SEE RECORD FOR DETIALS Assignors: CITIBANK, N.A., INDIVIDUALLY AND AS AGENT FOR BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION, THE CHASE MANHATTAN BANK, N.A., THE FIRST NATIONAL BANK OF CHICAGO, TRUST COMPANY BANK, FIRST FREEPORT NATIONAL BANK OF BRAZOSPORT BANK OF TEXAS
Assigned to INTERMEDICS, INC. reassignment INTERMEDICS, INC. RELEASED BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CITICORP MULTILEASE (SEF), INC.
Assigned to CARBO-MEDICS, INC., INTERMEDICS INTRAOCULAR, INC., INTERMEDICS, INC., SURGITRONICS CORPORATION, INTERMEDICS CARDIASSIST, INC. reassignment CARBO-MEDICS, INC. RELEASED BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: CHASE COMMERCIAL CORPORATION
Assigned to CALCITEK, INC., A TEXAS CORP., NEUROMEDICS, INC., A TEXAS CORP., AMERICAN PACEMAKER CORPORATION, A MASSACHUSETTS CORP., INTERMEDICS CARDIASSIST, INC., A TEXAS CORP., SURGITRONICS CORPORATION, A TEXAS CORP., INTERMEDICS INTRAOCULAR, INC., A TEXAS CORP., CARBOMEDICS, INC., A TEXAS CORP., INTERMEDICS, INC., A TEXAS CORP. reassignment CALCITEK, INC., A TEXAS CORP. RELEASED BY SECURED PARTY (SEE DOCUMENT FOR DETAILS). Assignors: B. A. LEASING CORPORATION
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0247Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L29/00Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
    • A61L29/04Macromolecular materials
    • A61L29/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3621Extra-corporeal blood circuits
    • A61M1/3653Interfaces between patient blood circulation and extra-corporal blood circuit
    • A61M1/3655Arterio-venous shunts or fistulae
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M39/00Tubes, tube connectors, tube couplings, valves, access sites or the like, specially adapted for medical use
    • A61M39/02Access sites
    • A61M39/0247Semi-permanent or permanent transcutaneous or percutaneous access sites to the inside of the body
    • A61M2039/0261Means for anchoring port to the body, or ports having a special shape or being made of a specific material to allow easy implantation/integration in the body

Definitions

  • ABSTRACT An implantable through-the-skin prosthetic device for the permanent entry into the body for passage of liquid, conductors or the like.
  • the device includes a roughened synthetic resinous member that courses through the skin and subcutaneous tissues and into the body.
  • a roughened plastic cannula passes through the skin into the blood vessel itself.
  • a ball joint fitting for connection to the external circuits allows for one-handed operation by a trained patient.
  • a special reamer is provided for use with the shunt.
  • ROBERT A. ERSEK AT TORNEYS IMPLANTABLE PROSTHETIC PASS-THROUGH DEVICE This invention relates to device for the permanent entry into the body for passage of liquids, conductors, or the like where a permanent firm mechanical dry and germproof seal with the skin and subcutaneous tissues is desired.
  • Such devices are use ful, for example, in artificial dialysis where a shunt is inserted into a vein in the arm or leg of the patient and maintained for long periods of time.
  • Other devices such as heart pacemakers, bladder stimulators, blood pumps, and the like, which are externally powered require conducting cables or wires to extend through the skin.
  • the inner surface should minimize clotting; (2) The exterior surface should give minimal tissue reaction; (3) The exterior surface should allow some attachment to the tissues in order to anchor the cannula firmly in place; (4) The skin at the exit site should surround the cannula so that a seal is formed and weeping and granulation tissue are absent, (5) Cannula material should be elastic and move freely with the tissue as the arm is rotated; (6) Cannula should be able to withstand extended trauma without permanent damage, (7) Cannula should not occlude vessels at the cannulation site; (8) Cannula should have an easily replaceable tip to facilitate fitting any size vessel; (9) A simple clamp or method of attachment to the external circuit is needed; and (10) The cannula should lie close to the skin.
  • H6. 1 is a schematic plan view showing the shunt in place in the arm of a patient
  • FIG. 2 is an enlarged schematic illustration of the arterial portion ofthe shunt showing details of construction and showing the arterial cannula implanted in the body tissue;
  • F K]. 3 is a section on a somewhat enlarged scale on the line 3-3 ofFlG. 2;
  • FIG. 4 is an illustration of the reaming device used with the shunt.
  • the shunt including an implantable through-the-skin seal device, according to the present invention, indicated generally at 10 in FIG. 1 and shown in place in a foreami 11, comprises an arterial cannula 12 extending into the artery 13, a flexible occlusion member 14, a distal arterial segment 15 connected through a disengageable junction means 16 to a distal venous segment 17 connected by means of an occlusion member 18 to a venous cannula 19 inserted through the skin into a vein 20.
  • the shunt remains in place in the arm (or leg) of the patient between treatments, the blood flowing from the artery through one cannula through the shunt to the other cannula and back into the vein.
  • the junction means 16 is disengaged and the distal arterial segment l5 and distal venous segment 17 of the shunt are connected to the dialysis apparatus, the so-called artificial kidney.”
  • the semirigid arterial cannula 12 extends through an opening 21 in the skin 22 through the subcutaneous tissue 23 and into the end of severed artery 13.
  • the interior of the cannula is smooth throughout.
  • the intravascular tip portion 24 of the cannula is smooth and slightly tapered to facilitate insertion into the vessel.
  • the intermediate portion 25 of the cannula from adjacent the tapered smooth tip 24 to beyond its point of exit through the skin is roughened to create a myriad of hairy projections to enable an attachment to be achieved between the body tissue and the cannula.
  • a portion of the roughened surface extends into the vessel 13 to anchor the cannula and keep the vessel sealed around it.
  • the cannula-occlusion member junction can be made in the standard fashion using a steel crimp ring 27, or a suture, or similar means.
  • the smooth end 26 of the cannula is provided with a cufi 28 in the form of an externally thickened ring in order to assure a positive strong grip between the cannula and occlusion tubing.
  • the distal arterial segment 15 is similarly connected to the opposite end of the occlusion tubing 14.
  • the junctions are permanent, leakproof and pressureproof.
  • the disengageable junction means 16 connecting the distal arterial and venous segments 15 and 16, respectively, is in the form of a ball joint.
  • One of the distal segments has a bulbous male end 29.
  • the other segment is provided with mating bulbous socket 30 having a slightly outwardly flaring mouth forming the female end of the ball joint.
  • This ball joint junction means allows rapid and certain engagement and disengagement.
  • the ball joint junction members are relatively thin walled such that they may be deformed slightly when fit together so that the narrowest part of the mouth of the socket may have a slightly lesser diameter than the greatest diameter of the male member. Any pressure within the lumen tends to force the outer walls of the smaller male fitting 29 against the inner walls of the slightly larger female fitting 30, thus increasing the leakproofness and better seating the seal.
  • the inner blood path remains nearly uniform through such a connection. [t-is possible to disengage and reengage the ball joint with just one hand, allowing for self-dialysis by a trained patient.
  • the venous portion of the shunt essentially duplicates the arterial portion already described in detail.
  • the cannula segments and distal segments of the shunt are preferably formed from polytetrafluoroethylene (Teflon) which has the requisite properties of inertness, chemical resistance, compatibility with body tissues, workability, strength, and the like.
  • Teflon polytetrafluoroethylene
  • suitable materials include nylon, acetal resin (Delrin), polycarbonate resin (Leaxan), polyvinylchloride, polyvinylidenechloride, and the like, compounded so as to have the requisite semirigidity to form a noncollapsible tube.
  • medical grade silicone rubber Silicon is the preferred material for the occlusion members although other flexible natural and synthetic rubber or rubberlike materials having the required properties of inertness chemical resistance, etc., may be used.
  • the desired roughness of the intermediate portion of the cannula segments which transverse the blood vessel lumen and the subcutaneous tract was achieved by turning the tubing on a lathe and applying a roughening tool.
  • the tube is inserted over a steel mandrel to prevent deformation of the tubing, the lathe was rotated at about 600 rpm. and the machining tool was made from a hacksaw blade and piece of brass stock.
  • the teeth of the hacksaw blade are allowed to very carefully gouge just the outer few thousandths of an inch of the tubing.
  • thousands of roughened hairy projections are created.
  • the hairy projections are integral with the body of the tubing.
  • Great care, of course, is exercised in order that the lumen is not entered or the tubing deformed.
  • the cuff 28 at the ends of the cannula and distal segments can be formed by forcing the tubing back on itself while being heated and placed within a forming jig.
  • the shunt may be reamed by use of a flexible elongated wire, as shown in FIG. 4.
  • the reamer 35 comprises an elongated central flexible wire core 36, which may be a singlestrand or a multiple-strand cable.
  • the core 36 is wrapped along its length by a coil spring 37 of small diameter.
  • the reamer has a smooth bulbous termination 38 at one end and a manipulative device in the form of a small ball configuration 39 at the other end.
  • the first end has a permanent slightly angled bend 40 deviating by about 40 to 50 from the longitudinal axis of the cable and spaced inwardly about 1 to 3 inches from the bulbous end.
  • the reamer ranges in length from about 2 to 3 feet.
  • the remotely angled bend can be controlled from the opposite end by manipulation of the ball element 39.
  • guinea pigs received a roughened Teflon tube but herein were allowed 21 days to become embedded and a Zby 4 inch circle of skin was removed and pressure applied by pneumatic piston to determine what force was needed to disrupt the skin-Teflon seal.
  • the 21-day implanted rough Teflon segments were disrupted by pressure calculated at 720 mm. Hg.
  • the skin Teflon seal was watertight until the bursting pressure was attained.
  • Photomicrographs show that a good junction was formed between the epithelial layers of the skin and the exit site of the cannula. There was never any pain associated with this shunt and the patient remained afebrile with a dry exit site throughout her hospital course. No infection was noted in either of these two, even though the second patient forgot about her shunt and completely submerged the arm in her bath water during the sixth week.
  • the leak pressure of the ball joint was tested by placing a closed ball joint seal in series with a mercury manometer and pumping the system full of fluid and measuring the pressure on the mercury manometer. Five ball joints were subjected to 300 mm. HG pressure without leak or bursting.
  • the potential defect herein occupied by the prosthesis becomes smaller and smaller, until pressure exerted by advancing cells exceeds that pressure under which they can continue to proliferate. By that time a firm mechanical seal is effected.
  • the strength of the seal is related to the number of surface grooves and projections on the rough Teflon surface and the strength of the fibrous tissue that embraces them.
  • the guinea pig skin accepting the roughened tube is a measure of the affinity for implantation, since all the smooth tubes fell out of the guinea pigs skin. To withstand pressures without leaks points out the intimacy of the seal as is further implied in photomicrographs where a close juxtaposition of the tissues and the Teflon is shown.
  • the slight taper and smooth leading edge of the intravascular portion of the cannula facilitates its insertion, since the roughened surface requires some force for sliding but follows the few smooth millimeter at its tip with ease.
  • the skin itself grows into the roughened surface and forms a seal.
  • the short (2 to 3 cm.) subcutaneous path and gentle turns of this shunt decrease the tissue damage and scar formation at a given shunt site, and hence allows greater number of shunt sites per limb. This is especially important in the chronic uremic whose life is dependent on the availability of shunt sites.
  • the new arteriovenous shunt meets the -point criteria outlined by Scribner as wellas current materials will allow. Since there are fewer parts than other designs, and since mass production can be simple, significant cost reduction can be effected.
  • the prosthetic device may be made in tubular form, as a cannula. Then, after implantation of the roughened tubular member through the skin and subcutaneous tract, the conductors may be mechanically sealed within the tubular passage. The device may be utilized whenever a permanent or semipermanent sealed passage through the skin is desirable or necessary.
  • An implantable through-the-skin prosthetic cannula device for making a firm dry germproof mechanical seal comprising:
  • said roughened surface consisting of a plurality of integral closely spaced hairlike projecting fibers whereby tissue ingrowth into and among said projecting fibers is promoted when said tube is implanted into living body tissue.
  • a device according to claim 1 further characterized in that said synthetic resinous tube is formed from polytetrafluoroethylene resin.
  • a method of making a firm dry germproof mechanically sealed passage through the skin of a living being which comprises implanting a tubular device according to claim 1 extending through the cutaneous and subcutaneous tissue of a living being and maintaining therein by means of attachment between the body tissues and roughened surface of the tube.
  • An arteriovenous shunt comprising:
  • C. occlusion means connecting each of said distal segments with a cannula segment
  • junction means comprises a bulbous male member on one of said distal segments and a mating female socket member on the other of said distal segments.
  • An arteriovenous shunt according to claim 4 further characterized in that the outer surface of the tip of each of said cannula segments opposite from said occlusion means is smooth and tapered.
  • An arteriovenous shunt according to claim 4 further characterized in that:
  • said occlusion means comprises a length of flexible tubing extending telescopically over the ends of the cannula segments and distal segments connected thereby,
  • C. means are provided to secure the ends of said occlusion means to the ends of said cannula segments and distal segments spaced inwardly from said cuffs.
  • An arteriovenous shunt according to claim 4 further characterized in that said cannula segments and said distal segments are formed from polytetrafluoroethylene resin.
  • An arteriovenous shunt according to claim 4 further characterized in that said occlusion means is formed from silicone rubber tubing.
  • An arteriovenous shunt according to claim 5 further characterized in that:
  • said mating male and female members are relatively thin walled
  • the open end of said female member is of diameter less than the outer diameter of the bulbous male member such that slight deformation of said members occurs during engagement and disengagement of the members.
  • An arteriovenous shunt comprising:
  • tubular silicone rubber occlusion means extending telescopically over the ends of each of said respective cannula segments and distal segments connecting the same, and
  • disengageable junction means between said distal segments comprising a bulbous male member on one of said segments and a mating female socket member on the other of said segments.

Abstract

An implantable through-the-skin prosthetic device for the permanent entry into the body for passage of liquid, conductors or the like. The device includes a roughened synthetic resinous member that courses through the skin and subcutaneous tissues and into the body. This special roughening promotes tissue ingrowth and thus effects a firm mechanical seal. Animal experimentation and clinical success imply that the seal is also dry and germproof. One form of such a device is an arteriovenous shunt for use in artificial dialysis. A roughened plastic cannula passes through the skin into the blood vessel itself. A ball joint fitting for connection to the external circuits allows for one-handed operation by a trained patient. A special reamer is provided for use with the shunt.

Description

United States atent Ersek [541 IMPLANTABLE PROSTHETIC PASS- THROUGH DEVICE [72] Inventor: Robert A. Ersek, St. Louis Park, Minn.
[73] Assignee: The Regents of the University of Minnesota, Minneapolis, Minn.
[22] Filed: July 7, 1969 211 Appl. No.: 839,297
[ 1 Feb. 1, 1972 3,508,554 4/1970 Sheridan 1 28/348 3,521,620 7/1970 Cook ..128/348 X OTHER PUBLICATIONS McDonald et :11, Trans. Amer. Soc. Artif. lnt. Organs, V01. XlVJune 1968,pp. 176-180 Primary ExaminerDalton L. Truluck Attorney-Burd, Braddock 8L Bartz 5 7] ABSTRACT An implantable through-the-skin prosthetic device for the permanent entry into the body for passage of liquid, conductors or the like. The device includes a roughened synthetic resinous member that courses through the skin and subcutaneous tissues and into the body. This special roughening promotes tissue ingrowth and thus effects a firm mechanical seal. Animal experimentation and clinical success imply that the seal is also dry and germproof. One form of such a device is an arteriovenous shunt for use in artificial dialysis. A roughened plastic cannula passes through the skin into the blood vessel itself. A ball joint fitting for connection to the external circuits allows for one-handed operation by a trained patient. A special reamer is provided for use with the shunt.
11 Claims, 4 Drawing Figures PATENTED nae 1m 1638.649
.2 1 C5. 4 INVIa/v'mR.
ROBERT A. ERSEK AT TORNEYS IMPLANTABLE PROSTHETIC PASS-THROUGH DEVICE This invention relates to device for the permanent entry into the body for passage of liquids, conductors, or the like where a permanent firm mechanical dry and germproof seal with the skin and subcutaneous tissues is desired. Such devices are use ful, for example, in artificial dialysis where a shunt is inserted into a vein in the arm or leg of the patient and maintained for long periods of time. Other devices such as heart pacemakers, bladder stimulators, blood pumps, and the like, which are externally powered require conducting cables or wires to extend through the skin. These have been a source of irritation and infection since, prior to the present invention, no safe dry and germproof mechanical seal through the skin was possible. The invention is described with particular reference to an implantable tubular arteriovenous shunt for use by patients suffering from renal failure and undergoing artificial dialysis, although it must be understood that the invention is not so limited.
There are approximately 50,000 Americans contracting renal failure each year. Of these, some l0,000 are qualified for dialysis or transplantation. Each year as patients are saved by these modalities, additional facilities are needed to accommodate the new patients as well as those previously helped. Thus, there is an expanding need for improvement in the treatment of renal failure.
Since the demonstration of the feasibility of artificial dialysis by Kolff, in the mid l940s, great efforts have been directed to the improvement of methods for gaining access to the bloodstream. In 1960, Quinton and Scribner (Quinton, W., Dillard, D. H. and Scribner, B. H., Cannulation of blood vessels for prolonged hemodialysis. Trans. Am. Sm. for Artzf. Int. Organs, 6: 104, l960.) described a Teflon shunt system that allowed long term implantation and repeated dialysis. Although many minor variations have been brought forth, the basic device remains similar to the original design except that silicone rubber tubing is used for the subcutaneous and exterior sections. Successful cannulations have been reported for as long as years.
In 1961, Quinton and Scribner (Quinton, W. E., Dillard, D. d., Cole, J. J. and Scribner, B. H. Possible improvements in the technique of long term cannulation of blood vessels. Trans, Am. Soc. for Artzf. Int. Organs, 7: 60, 1960.) defined the ideal cannula as having major properties. They are: (l) The inner surface should minimize clotting; (2) The exterior surface should give minimal tissue reaction; (3) The exterior surface should allow some attachment to the tissues in order to anchor the cannula firmly in place; (4) The skin at the exit site should surround the cannula so that a seal is formed and weeping and granulation tissue are absent, (5) Cannula material should be elastic and move freely with the tissue as the arm is rotated; (6) Cannula should be able to withstand extended trauma without permanent damage, (7) Cannula should not occlude vessels at the cannulation site; (8) Cannula should have an easily replaceable tip to facilitate fitting any size vessel; (9) A simple clamp or method of attachment to the external circuit is needed; and (10) The cannula should lie close to the skin.
In spite of many refinements, several problems have remained unsolved in the prior art shunts. The exit sites of the silicone rubber cannula are usually long sinus tracts that must be meticulously cleaned and are a constant septic threat to the patient. The junction means for connection to the external circuits are cumbersome, undependable, and require at least two hands to manipulate. The many turned lumen prevents easy reaming of those shunts should an occlusion occur. The newly developed shunt which is the subject of the present invention is directed toward solving these problems.
The arteriovenous shunt, according to the present invention, is illustrated in the accompanying drawings in which:
H6. 1 is a schematic plan view showing the shunt in place in the arm of a patient;
FIG. 2 is an enlarged schematic illustration of the arterial portion ofthe shunt showing details of construction and showing the arterial cannula implanted in the body tissue;
F K]. 3 is a section on a somewhat enlarged scale on the line 3-3 ofFlG. 2; and
FIG. 4 is an illustration of the reaming device used with the shunt.
Referring now to the drawings, the shunt, including an implantable through-the-skin seal device, according to the present invention, indicated generally at 10 in FIG. 1 and shown in place in a foreami 11, comprises an arterial cannula 12 extending into the artery 13, a flexible occlusion member 14, a distal arterial segment 15 connected through a disengageable junction means 16 to a distal venous segment 17 connected by means of an occlusion member 18 to a venous cannula 19 inserted through the skin into a vein 20. As is well understood, the shunt remains in place in the arm (or leg) of the patient between treatments, the blood flowing from the artery through one cannula through the shunt to the other cannula and back into the vein. During his periodic dialysis treatments, the junction means 16 is disengaged and the distal arterial segment l5 and distal venous segment 17 of the shunt are connected to the dialysis apparatus, the so-called artificial kidney."
As best seen in FIG. 2, the semirigid arterial cannula 12 extends through an opening 21 in the skin 22 through the subcutaneous tissue 23 and into the end of severed artery 13. The interior of the cannula is smooth throughout. The intravascular tip portion 24 of the cannula is smooth and slightly tapered to facilitate insertion into the vessel. The intermediate portion 25 of the cannula from adjacent the tapered smooth tip 24 to beyond its point of exit through the skin is roughened to create a myriad of hairy projections to enable an attachment to be achieved between the body tissue and the cannula. A portion of the roughened surface extends into the vessel 13 to anchor the cannula and keep the vessel sealed around it.
After the cannula exits the skin, it is again smooth and is fitted to a collapsibly deformable tubular occlusion member 14 which can be squeezed closed by any suitable clamp during attachment of the shunt device to and release from the dialysis apparatus. The cannula-occlusion member junction can be made in the standard fashion using a steel crimp ring 27, or a suture, or similar means. Desirably, however, the smooth end 26 of the cannula is provided with a cufi 28 in the form of an externally thickened ring in order to assure a positive strong grip between the cannula and occlusion tubing. The distal arterial segment 15 is similarly connected to the opposite end of the occlusion tubing 14. The junctions are permanent, leakproof and pressureproof.
The disengageable junction means 16 connecting the distal arterial and venous segments 15 and 16, respectively, is in the form of a ball joint. One of the distal segments has a bulbous male end 29. The other segment is provided with mating bulbous socket 30 having a slightly outwardly flaring mouth forming the female end of the ball joint. This ball joint junction means allows rapid and certain engagement and disengagement. The ball joint junction members are relatively thin walled such that they may be deformed slightly when fit together so that the narrowest part of the mouth of the socket may have a slightly lesser diameter than the greatest diameter of the male member. Any pressure within the lumen tends to force the outer walls of the smaller male fitting 29 against the inner walls of the slightly larger female fitting 30, thus increasing the leakproofness and better seating the seal. The inner blood path remains nearly uniform through such a connection. [t-is possible to disengage and reengage the ball joint with just one hand, allowing for self-dialysis by a trained patient. Apart from the male-female ball joint members, the venous portion of the shunt essentially duplicates the arterial portion already described in detail.
The cannula segments and distal segments of the shunt are preferably formed from polytetrafluoroethylene (Teflon) which has the requisite properties of inertness, chemical resistance, compatibility with body tissues, workability, strength, and the like. Other suitable materials, though less desirable, include nylon, acetal resin (Delrin), polycarbonate resin (Leaxan), polyvinylchloride, polyvinylidenechloride, and the like, compounded so as to have the requisite semirigidity to form a noncollapsible tube. Similarly, medical grade silicone rubber (Siliastic) is the preferred material for the occlusion members although other flexible natural and synthetic rubber or rubberlike materials having the required properties of inertness chemical resistance, etc., may be used.
The desired roughness of the intermediate portion of the cannula segments which transverse the blood vessel lumen and the subcutaneous tract was achieved by turning the tubing on a lathe and applying a roughening tool. The tube is inserted over a steel mandrel to prevent deformation of the tubing, the lathe was rotated at about 600 rpm. and the machining tool was made from a hacksaw blade and piece of brass stock. The teeth of the hacksaw blade are allowed to very carefully gouge just the outer few thousandths of an inch of the tubing. As the tubing spins in contact with the roughening tool, thousands of roughened hairy projections are created. As is apparent, the hairy projections are integral with the body of the tubing. Great care, of course, is exercised in order that the lumen is not entered or the tubing deformed.
The cuff 28 at the ends of the cannula and distal segments can be formed by forcing the tubing back on itself while being heated and placed within a forming jig.
The shunt may be reamed by use of a flexible elongated wire, as shown in FIG. 4. The reamer 35 comprises an elongated central flexible wire core 36, which may be a singlestrand or a multiple-strand cable. The core 36 is wrapped along its length by a coil spring 37 of small diameter. The reamer has a smooth bulbous termination 38 at one end and a manipulative device in the form of a small ball configuration 39 at the other end. The first end has a permanent slightly angled bend 40 deviating by about 40 to 50 from the longitudinal axis of the cable and spaced inwardly about 1 to 3 inches from the bulbous end. The reamer ranges in length from about 2 to 3 feet. The remotely angled bend can be controlled from the opposite end by manipulation of the ball element 39. By pushing the reamer into the lumen of the shunt and flexing and straightening the ball end, any turns can be followed and the smooth finish of he reamer protects the inner lumen from scratches.
In order to assess the efficacy of the pass through design, animal experiments were conducted to determine if the connective tissue would grow into and become attached to the roughened cannula (Teflon) surface, if sepsis could be avoided, and if strength could be expected from such a seal. In the initial series, a single U-shaped piece of Teflon tubing with one limb of the U roughened and the other smooth, was implanted beneath the skin of two dogs. The skin was completely closed over the tubing, since previous tests were thwarted by the dogs removing the device, no matter what steps were taken to restrain them. A single U-shaped piece of Teflon was employed in order that the very same piece of stock would be used and thus serve as its own control, and so that photomicrographs could be taken of the two limbs of the U.
When the skin and subcutaneous tissue containing the tubes were removed, a firm grip of the roughened segment was noted and no grip of the smooth area was seen. Photomicrographs of the two ends of the same U-shaped piece of tubing show connective tissue tenaciously involved with the roughened portion and the smooth portion remaining discretely uninvolved.
In a second series of experiments guinea pigs were used and a roughened and a smooth Teflon tube was implanted into the dorsal surface thereof through a small skin puncture into the underlying tissue. Two percent Xylocaine was infiltrated into the area for anesthesia and each animal received five drops of a mixture of 1 million units penicillin and 1 gram streptomycin orally. These devices were then removed after l4 to days for inspection. The skin and underlying connective tissue grew into the roughened tube but all smooth segments fell out spontaneously, even though a circumferential bandage was applied in order to prevent the dislodgment by the guinea pigs, and the roughened tubes just a few millimeters away remained intact.
In other experiments 10 guinea pigs received a roughened Teflon tube but herein were allowed 21 days to become embedded and a Zby 4 inch circle of skin was removed and pressure applied by pneumatic piston to determine what force was needed to disrupt the skin-Teflon seal. The 21-day implanted rough Teflon segments were disrupted by pressure calculated at 720 mm. Hg. The skin Teflon seal was watertight until the bursting pressure was attained.
Shunts incorporating the roughened Teflon cannula were then implanted in three uremic patients. The shunt in one patient remained clot free for more than 8 weeks. In the first case the shunt clotted several times after 1 day and 1 night. and was replaced by a prior art shunt, which also clotted several times. The patient went on to recovery of his acute tubular necrosis in 24 days. The second patient, a 45-year-old white female with acute tubular necrosis following pancreatitis was placed on dialysis acutely and after 4 weeks began to have urine output and her uremia slowly receded. Her shunt remained patent through this course and the skin ans subcutaneous tissue became well involved within the roughened surface of the shunt. Photomicrographs show that a good junction was formed between the epithelial layers of the skin and the exit site of the cannula. There was never any pain associated with this shunt and the patient remained afebrile with a dry exit site throughout her hospital course. No infection was noted in either of these two, even though the second patient forgot about her shunt and completely submerged the arm in her bath water during the sixth week.
The leak pressure of the ball joint was tested by placing a closed ball joint seal in series with a mercury manometer and pumping the system full of fluid and measuring the pressure on the mercury manometer. Five ball joints were subjected to 300 mm. HG pressure without leak or bursting.
The use of all Teflon members to transverse the vessel lumen and the subcutaneous tract enables an attachment to be achieved between the tissue and the rosthesis if the Teflon has been roughened. The seal obtained appears to be a mechanical seal but a tight one, as evidenced by the tests. This is a logical result if we examine the basic processes of wound healing by secondary intention whereby new cells are added to the advancing wound edge, thus the roughened surface presents many facets, angles and geometric projections .for the advancing connective tissue cells to become entangled in and mechanically intertwine.
As the cells multiply at the circular wound edge, the potential defect herein occupied by the prosthesis becomes smaller and smaller, until pressure exerted by advancing cells exceeds that pressure under which they can continue to proliferate. By that time a firm mechanical seal is effected. The strength of the seal is related to the number of surface grooves and projections on the rough Teflon surface and the strength of the fibrous tissue that embraces them. The guinea pig skin accepting the roughened tube is a measure of the affinity for implantation, since all the smooth tubes fell out of the guinea pigs skin. To withstand pressures without leaks points out the intimacy of the seal as is further implied in photomicrographs where a close juxtaposition of the tissues and the Teflon is shown.
The slight taper and smooth leading edge of the intravascular portion of the cannula facilitates its insertion, since the roughened surface requires some force for sliding but follows the few smooth millimeter at its tip with ease. The skin itself grows into the roughened surface and forms a seal. Study of the photomicrographs, in addition to showing the mechanical interdigitation between the tissue and the Teflon, points out the germproof nature of this seal since the cells adjacent to the Teflon seem to be mostly fibroblasts without significant inflammation or foreign body reaction. The short (2 to 3 cm.) subcutaneous path and gentle turns of this shunt decrease the tissue damage and scar formation at a given shunt site, and hence allows greater number of shunt sites per limb. This is especially important in the chronic uremic whose life is dependent on the availability of shunt sites.
The new arteriovenous shunt, according to this invention, meets the -point criteria outlined by Scribner as wellas current materials will allow. Since there are fewer parts than other designs, and since mass production can be simple, significant cost reduction can be effected.
In the case of a lead-through for electrical conductors, as for a cardiac pacemaker or the like, the prosthetic device may be made in tubular form, as a cannula. Then, after implantation of the roughened tubular member through the skin and subcutaneous tract, the conductors may be mechanically sealed within the tubular passage. The device may be utilized whenever a permanent or semipermanent sealed passage through the skin is desirable or necessary.
The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:
1. An implantable through-the-skin prosthetic cannula device for making a firm dry germproof mechanical seal, said device comprising:
A. a flexible inert nontoxic synthetic resinous tube of length and subcutaneous tissue ofa living being,
B. at least a portion of the length of said tube at least sufficient to extend through said cutaneous and subcutaneous tissue having a roughened outer surface,
C. said roughened surface consisting of a plurality of integral closely spaced hairlike projecting fibers whereby tissue ingrowth into and among said projecting fibers is promoted when said tube is implanted into living body tissue.
2. A device according to claim 1 further characterized in that said synthetic resinous tube is formed from polytetrafluoroethylene resin.
3. A method of making a firm dry germproof mechanically sealed passage through the skin of a living being which comprises implanting a tubular device according to claim 1 extending through the cutaneous and subcutaneous tissue of a living being and maintaining therein by means of attachment between the body tissues and roughened surface of the tube.
4. An arteriovenous shunt comprising:
A. a pair of cannula segments according to claim 1, each having a roughened outer surface intermediate of their ends,
B. a distal arterial segment and a distal venous segment,
C. occlusion means connecting each of said distal segments with a cannula segment, and
D. disengageable junction means between said distal segments.
5. An arteriovenous shunt according to claim 4 further characterized in that said junction means comprises a bulbous male member on one of said distal segments and a mating female socket member on the other of said distal segments.
6. An arteriovenous shunt according to claim 4 further characterized in that the outer surface of the tip of each of said cannula segments opposite from said occlusion means is smooth and tapered.
7. An arteriovenous shunt according to claim 4 further characterized in that:
A. said occlusion means comprises a length of flexible tubing extending telescopically over the ends of the cannula segments and distal segments connected thereby,
B. the ends of said cannula segments and distal segments telescoped within the ends of the occlusion means are provided with a cuff of enlarged exterior diameter, and
C. means are provided to secure the ends of said occlusion means to the ends of said cannula segments and distal segments spaced inwardly from said cuffs.
8. An arteriovenous shunt according to claim 4 further characterized in that said cannula segments and said distal segments are formed from polytetrafluoroethylene resin.
9. An arteriovenous shunt according to claim 4 further characterized in that said occlusion means is formed from silicone rubber tubing.
An arteriovenous shunt according to claim 5 further characterized in that:
A. said mating male and female members are relatively thin walled,
B. said male member mates with a close sealing fit in said female member, and
C. the open end of said female member is of diameter less than the outer diameter of the bulbous male member such that slight deformation of said members occurs during engagement and disengagement of the members.
11. An arteriovenous shunt comprising:
A. a semirigid tubular arterial cannula segment and a semirigid tubular venous cannula segment formed from polytetrafiuoroethylene resin,
B. a roughened outer surface composed of a plurality of closely spaced hairlike projecting fibers intermediate of the ends of each of said cannula segments,
C. a smooth and tapered outer surface intravascular tip on each of said cannula segments,
D. a distal arterial segment and a distal venous segment formed from polytetrafluoroethylene resin,
E. tubular silicone rubber occlusion means extending telescopically over the ends of each of said respective cannula segments and distal segments connecting the same, and
F. disengageable junction means between said distal segments comprising a bulbous male member on one of said segments and a mating female socket member on the other of said segments.
g g UNITED STATES PATENT OFFICE CERTIFICATE OF CORRECTION Patent No. 3 ,638 ,649 Dated February 1 1972 Inventor) Robert A. Ersek It is certified that error appears in the above-identified patent and that said Letters Patent are hereby corrected as shown below:
Column 1, line 1, after "to", an implantable through-theskin prostheticis omitted.
Column 1, lines 39-40, "Dillard, D. d." should be -Dillard, D. H.
Column 3, line 40, "he" should be the-- Column 4, line 22, "ans" should be -and- Column 5, line 2 1, after "length", -at least sufficient to extend through the cutaneousis omitted.
Signed and sealed this 13th day of June 1972.
(small) Attest:
EDWARD MELETCHEEJR. ROBERT GQTTSCHALK Attesting @fficer Commissioner of Patents

Claims (11)

1. An implantable through-the-skin prosthetic cannula device for making a firm dry germproof mechanical seal, said device comprising: A. a flexible inert nontoxic synthetic resinous tube of length and subcutaneous tissue of a living being, B. at least a portion of the length of said tube at least sufficient to extend through said cutaneous and subcutaneous tissue having a roughened outer surface, C. said roughened surface consisting of a plurality of integral closely spaced hairlike projecting fibers whereby tissue ingrowth into and among said projecting fibers is promoted when said tube is implanted into living body tissue.
2. A device according to claim 1 further characterized in that said synthetic resinous tube is formed from polytetrafluoroethylene resin.
3. A method of making a firm dry germproof mechanically sealed passage through the skin of a living being which comprises implanting a tubular device according to claim 1 extending through the cutaneous and subcutaneous tissue of a living being and maintaining therein by means of attachment between the body tissues and roughened surface of the tube.
4. An arteriovenous shunt comprising: A. a pair of cannula segments according to claim 1, each having a roughened outer surface intermediate of their ends, B. a distal arterial segment and a distal venous segment, C. occlusion means connecting each of said distal segments with a cannula segment, and D. disengageable junction means between said distal segments.
5. An arteriovenous shunt according to claim 4 further characterized in that said junction means comprises a bulbous male member on one of said distal segments and a mating female socket member on the other of said distal segments.
6. An arteriovenous shunt according to claim 4 further characterized in that the outer surface of the tip of each of said cannula segments opposite from said occlusion means is smooth and tapered.
7. An arteriovenous shunt according to claim 4 further characterized in that: A. said occlusion means comprises a length of flexible tubing extending telescopically over the ends of the cannula segments and distal segments connected thereby, B. the ends of said cannula segments and distal segments telescoped within the ends of the occlusion means are provided with a cuff of enlarged exterior diameter, and C. means are provided to secure the ends of said occlusion means to the ends of said cannula segments and distal segments spaced inwardly from said cuffs.
8. An arteriovenous shunt according to claim 4 further characterized in that said cannula segments and said distal segments are formed from polytetrafluoroethylene resin.
9. An arteriovenous shunt according to claim 4 further characterized in that said occlusion means is formed from silicone rubber tubing.
10. An arteriovenous shunt according to claim 5 further characterized in that: A. said mating male and female members are relatively thin walled, B. said male member mates with a close sealing fit in said female member, and C. the open end of said female member is of diameter less than the outer diameter of the bulbous male member such that slight deformation of said members occurs during engagement and disengagement of the members.
11. An arteriovenous shunt comprising: A. a semirigid tubular arterial cannula segment and a semirigid tubular venous cannula segment formed from polytetrafluoroethylene resin, B. a roughened outer surface composed of a plurality of closely spaced hairlike projecting fibers intermediate of the ends of each of said cannula segments, C. a smooth and tapered outer surface intravascular tip on each of said cannula segments, D. a distal arterial segment and a distal venous segment formed from polytetrafluoroethylene resin, E. tubular silicone rubber occlusion means extendinG telescopically over the ends of each of said respective cannula segments and distal segments connecting the same, and F. disengageable junction means between said distal segments comprising a bulbous male member on one of said segments and a mating female socket member on the other of said segments.
US839297A 1969-07-07 1969-07-07 Implantable prosthetic pass-through device Expired - Lifetime US3638649A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US83929769A 1969-07-07 1969-07-07

Publications (1)

Publication Number Publication Date
US3638649A true US3638649A (en) 1972-02-01

Family

ID=25279353

Family Applications (1)

Application Number Title Priority Date Filing Date
US839297A Expired - Lifetime US3638649A (en) 1969-07-07 1969-07-07 Implantable prosthetic pass-through device

Country Status (1)

Country Link
US (1) US3638649A (en)

Cited By (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3765032A (en) * 1972-09-27 1973-10-16 J Palma Implant
US3826257A (en) * 1972-07-14 1974-07-30 T Buselmeier Prosthetic shunt
US3882862A (en) * 1974-01-11 1975-05-13 Olga Berend Arteriovenous shunt
FR2400908A1 (en) * 1977-05-31 1979-03-23 Parks Leon METHOD AND APPARATUS FOR HYPERTHMIC TREATMENT
US4192302A (en) * 1978-09-12 1980-03-11 Boddie Arthur W Hepatic isolation and perfusion circuit assembly
US4447237A (en) * 1982-05-07 1984-05-08 Dow Corning Corporation Valving slit construction and cooperating assembly for penetrating the same
US4479798A (en) * 1977-05-31 1984-10-30 Research Against Cancer, Inc. Subcutaneous implant useful in effecting hyperthermic treatment
EP0202917A2 (en) * 1985-05-23 1986-11-26 Kureha Kagaku Kogyo Kabushiki Kaisha Implant device
US4676782A (en) * 1984-09-21 1987-06-30 Vitaphore Corporation Positionable tissue interfacing device for the management of percutaneous conduits
US4899414A (en) * 1988-09-19 1990-02-13 Irwin James K Polished surface protective sleeve for covering the electrical cord of a car wax polishing and buffing machine
US5141499A (en) * 1991-10-09 1992-08-25 Zappacosta Anthony R Peritoneal dialysis catheter
US5147483A (en) * 1989-04-26 1992-09-15 Therex Corporation Implantable infusion device and method of manufacture thereof
US5336263A (en) * 1992-04-06 1994-08-09 Robert A. Ersek Treatment of urological and gastric fluid reflux disorders by injection of mmicro particles
WO1995007111A1 (en) * 1993-09-10 1995-03-16 Angelchik Jean P Method and apparatus removing fluid from abdomen
US5468221A (en) * 1989-09-14 1995-11-21 Schoener; Wolfgang Implantable catheter made of high cold flow material
US5603698A (en) * 1993-04-13 1997-02-18 Boston Scientific Corporation Prosthesis delivery system
US5792478A (en) * 1996-07-08 1998-08-11 Advanced Uro Science Tissue injectable composition and method of use
US5848987A (en) * 1996-04-30 1998-12-15 Medtronic, Inc. Microtextured catheter and method for preventing catheter fluid reflux
US5882341A (en) * 1995-07-07 1999-03-16 Bousquet; Gerald G. Method of providing a long-lived window through the skin to subcutaneous tissue
US5902333A (en) * 1993-04-13 1999-05-11 Boston Scientific Corporation Prosthesis delivery system with dilating tip
US5984896A (en) * 1997-10-28 1999-11-16 Ojp #73, Inc. Fixated catheter
WO1999065559A1 (en) * 1998-06-19 1999-12-23 Klinični center Ljubljana Hose for making an artificial vessel
US6086553A (en) * 1999-07-01 2000-07-11 Akbik; Mohamad J. Arteriovenous shunt
US6338724B1 (en) 1999-03-29 2002-01-15 Christos D. Dossa Arterio-venous interconnection
US6459917B1 (en) 2000-05-22 2002-10-01 Ashok Gowda Apparatus for access to interstitial fluid, blood, or blood plasma components
WO2003020342A1 (en) * 2001-08-31 2003-03-13 Disetronic Licensing Ag Implant with a surface structure
US20040044330A1 (en) * 2002-02-19 2004-03-04 Changqing Li Medical catheter assembly including multi-piece connector
US20040122438A1 (en) * 2002-12-23 2004-06-24 Boston Scientific Corporation Flex-tight interlocking connection tubing for delivery of bone cements/biomaterials for vertebroplasty
US20040225254A1 (en) * 2003-05-07 2004-11-11 Don Tanaka Localized pleurodesis chemical delivery
US20040231674A1 (en) * 2003-05-20 2004-11-25 Don Tanaka Intra/extra-thoracic collateral ventilation bypass system
US20040237966A1 (en) * 2003-05-29 2004-12-02 Don Tanaka Methods and devices to assist pulmonary decompression
US20040244803A1 (en) * 2003-06-05 2004-12-09 Don Tanaka Intra-thoracic collateral ventilation bypass system
US20050025816A1 (en) * 2003-07-15 2005-02-03 Don Tanaka Methods and devices to accelerate wound healing in thoracic anastomosis applications
US20060107961A1 (en) * 2004-11-19 2006-05-25 Don Tanaka Localized pleurodesis evacuation device
US20060118126A1 (en) * 2004-11-19 2006-06-08 Don Tanaka Methods and devices for controlling collateral ventilation
US20060118125A1 (en) * 2004-11-19 2006-06-08 Don Tanaka Pulmonary drug delivery
US20060124126A1 (en) * 2004-12-10 2006-06-15 Don Tanaka Collateral ventilation device with chest tube/evacuation features
US20070051372A1 (en) * 2005-08-23 2007-03-08 Don Tanaka Collateral ventilation bypass system with retention features
US20070163598A1 (en) * 2006-01-17 2007-07-19 Asia Chang Variable resistance pulmonary ventilation bypass valve
US20070270776A1 (en) * 2003-06-03 2007-11-22 Respira, Inc. Lung reduction system
US7361158B1 (en) * 1999-09-24 2008-04-22 Medicinvent, Llc Catheter including textured interface
US20080281295A1 (en) * 2007-05-11 2008-11-13 Portaero, Inc. Visceral pleura ring connector
US20080281433A1 (en) * 2007-05-11 2008-11-13 Portaero, Inc. Methods and devices to create a chemically and/or mechanically localized pleurodesis
US20080281151A1 (en) * 2007-05-11 2008-11-13 Portaero, Inc. Pulmonary pleural stabilizer
US20080287878A1 (en) * 2007-05-15 2008-11-20 Portaero, Inc. Pulmonary visceral pleura anastomosis reinforcement
US20080283065A1 (en) * 2007-05-15 2008-11-20 Portaero, Inc. Methods and devices to maintain patency of a lumen in parenchymal tissue of the lung
US20080295829A1 (en) * 2007-05-30 2008-12-04 Portaero, Inc. Bridge element for lung implant
US20090192469A1 (en) * 2008-01-24 2009-07-30 Istvan Bognar Devices and Methods for Development of a Scar Tissue Tunnel Track
US20090205645A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management method for the treatment of chronic obstructive pulmonary disease
US20090205641A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease
US20100076383A1 (en) * 2002-02-19 2010-03-25 Boston Scientific Scimed, Inc. Low profile adaptor for use with a medical catheter
US20100170507A1 (en) * 2009-01-08 2010-07-08 Portaero, Inc. Pneumostoma management device with integrated patency sensor and method
US20100204707A1 (en) * 2009-02-11 2010-08-12 Portaero, Inc. Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US20100286544A1 (en) * 2008-02-19 2010-11-11 Portaero, Inc. Methods and devices for assessment of pneumostoma function
US20110152775A1 (en) * 2009-12-23 2011-06-23 Jose Luis Lopez Ophthalmic valved trocar vent
US20110152774A1 (en) * 2009-12-23 2011-06-23 Jose Luis Lopez Ophthalmic valved trocar cannula
US8062315B2 (en) * 2007-05-17 2011-11-22 Portaero, Inc. Variable parietal/visceral pleural coupling
US9814869B1 (en) 1999-06-15 2017-11-14 C.R. Bard, Inc. Graft-catheter vascular access system

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1661759A (en) * 1925-04-18 1928-03-06 Frank R King Pipe cleaner
US2118631A (en) * 1935-04-03 1938-05-24 Wappler Frederick Charles Catheter stylet
US2462765A (en) * 1944-12-13 1949-02-22 Harnischfeger Corp Welded motor frame
US3447161A (en) * 1966-08-01 1969-06-03 Avco Corp Disinfectant dispensing percutaneous connector
US3461869A (en) * 1966-04-05 1969-08-19 Bio Medical Systems Inc Permanent skin exit device
US3482574A (en) * 1967-01-12 1969-12-09 Eastman Kodak Co Artificial kidney system provided with a lever actuated shunt coupling mechanism
US3484121A (en) * 1966-09-26 1969-12-16 Wayne E Quinton Cannula extension and connector apparatus
US3508554A (en) * 1968-11-04 1970-04-28 David S Sheridan Medico-surgical tubes having frosted surface
US3521620A (en) * 1967-10-30 1970-07-28 William A Cook Vascular coil spring guide with bendable tip

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1661759A (en) * 1925-04-18 1928-03-06 Frank R King Pipe cleaner
US2118631A (en) * 1935-04-03 1938-05-24 Wappler Frederick Charles Catheter stylet
US2462765A (en) * 1944-12-13 1949-02-22 Harnischfeger Corp Welded motor frame
US3461869A (en) * 1966-04-05 1969-08-19 Bio Medical Systems Inc Permanent skin exit device
US3447161A (en) * 1966-08-01 1969-06-03 Avco Corp Disinfectant dispensing percutaneous connector
US3484121A (en) * 1966-09-26 1969-12-16 Wayne E Quinton Cannula extension and connector apparatus
US3482574A (en) * 1967-01-12 1969-12-09 Eastman Kodak Co Artificial kidney system provided with a lever actuated shunt coupling mechanism
US3521620A (en) * 1967-10-30 1970-07-28 William A Cook Vascular coil spring guide with bendable tip
US3508554A (en) * 1968-11-04 1970-04-28 David S Sheridan Medico-surgical tubes having frosted surface

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
McDonald et al., Trans. Amer. Soc. Artif. Int. Organs., Vol. XIV June 1968, pp. 176 180 *

Cited By (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3826257A (en) * 1972-07-14 1974-07-30 T Buselmeier Prosthetic shunt
US3765032A (en) * 1972-09-27 1973-10-16 J Palma Implant
US3882862A (en) * 1974-01-11 1975-05-13 Olga Berend Arteriovenous shunt
US4479798A (en) * 1977-05-31 1984-10-30 Research Against Cancer, Inc. Subcutaneous implant useful in effecting hyperthermic treatment
FR2400908A1 (en) * 1977-05-31 1979-03-23 Parks Leon METHOD AND APPARATUS FOR HYPERTHMIC TREATMENT
US4192302A (en) * 1978-09-12 1980-03-11 Boddie Arthur W Hepatic isolation and perfusion circuit assembly
US4447237A (en) * 1982-05-07 1984-05-08 Dow Corning Corporation Valving slit construction and cooperating assembly for penetrating the same
US4676782A (en) * 1984-09-21 1987-06-30 Vitaphore Corporation Positionable tissue interfacing device for the management of percutaneous conduits
EP0202917A2 (en) * 1985-05-23 1986-11-26 Kureha Kagaku Kogyo Kabushiki Kaisha Implant device
EP0202917A3 (en) * 1985-05-23 1987-09-23 Kureha Kagaku Kogyo Kabushiki Kaisha Implant device
US4899414A (en) * 1988-09-19 1990-02-13 Irwin James K Polished surface protective sleeve for covering the electrical cord of a car wax polishing and buffing machine
US5147483A (en) * 1989-04-26 1992-09-15 Therex Corporation Implantable infusion device and method of manufacture thereof
US5468221A (en) * 1989-09-14 1995-11-21 Schoener; Wolfgang Implantable catheter made of high cold flow material
US5141499A (en) * 1991-10-09 1992-08-25 Zappacosta Anthony R Peritoneal dialysis catheter
US5336263A (en) * 1992-04-06 1994-08-09 Robert A. Ersek Treatment of urological and gastric fluid reflux disorders by injection of mmicro particles
US5603698A (en) * 1993-04-13 1997-02-18 Boston Scientific Corporation Prosthesis delivery system
US5902333A (en) * 1993-04-13 1999-05-11 Boston Scientific Corporation Prosthesis delivery system with dilating tip
US5984964A (en) * 1993-04-13 1999-11-16 Boston Scientific Corporation Prothesis delivery system
WO1995007111A1 (en) * 1993-09-10 1995-03-16 Angelchik Jean P Method and apparatus removing fluid from abdomen
US5882341A (en) * 1995-07-07 1999-03-16 Bousquet; Gerald G. Method of providing a long-lived window through the skin to subcutaneous tissue
US6099508A (en) * 1995-07-07 2000-08-08 Bousquet; Gerald G. Transcutaneous access device
US5848987A (en) * 1996-04-30 1998-12-15 Medtronic, Inc. Microtextured catheter and method for preventing catheter fluid reflux
US5792478A (en) * 1996-07-08 1998-08-11 Advanced Uro Science Tissue injectable composition and method of use
US5984896A (en) * 1997-10-28 1999-11-16 Ojp #73, Inc. Fixated catheter
WO1999065559A1 (en) * 1998-06-19 1999-12-23 Klinični center Ljubljana Hose for making an artificial vessel
US6338724B1 (en) 1999-03-29 2002-01-15 Christos D. Dossa Arterio-venous interconnection
US9814869B1 (en) 1999-06-15 2017-11-14 C.R. Bard, Inc. Graft-catheter vascular access system
US9993633B2 (en) 1999-06-15 2018-06-12 C. R. Bard, Inc. Graft-catheter vascular access system
US6086553A (en) * 1999-07-01 2000-07-11 Akbik; Mohamad J. Arteriovenous shunt
US7361158B1 (en) * 1999-09-24 2008-04-22 Medicinvent, Llc Catheter including textured interface
US20020183604A1 (en) * 2000-05-22 2002-12-05 Ashok Gowda Apparatus for access to interstitial fluid, blood, or blood plasma components
US6459917B1 (en) 2000-05-22 2002-10-01 Ashok Gowda Apparatus for access to interstitial fluid, blood, or blood plasma components
WO2003020342A1 (en) * 2001-08-31 2003-03-13 Disetronic Licensing Ag Implant with a surface structure
US7766881B2 (en) 2001-08-31 2010-08-03 Roche Diagnostics International Ag Implant with surface structure
US8308713B2 (en) 2002-02-19 2012-11-13 Boston Scientific Scimed, Inc. Medical catheter assembly including multi-piece connector
US8187253B2 (en) 2002-02-19 2012-05-29 Boston Scientific Scimed, Inc. Low profile adaptor for use with a medical catheter
US20090182272A1 (en) * 2002-02-19 2009-07-16 Changqing Li Medical catheter assembly including multi-piece connector
US7507230B2 (en) * 2002-02-19 2009-03-24 Boston Scientific Scimed, Inc. Medical catheter assembly including multi-piece connector
US20100076383A1 (en) * 2002-02-19 2010-03-25 Boston Scientific Scimed, Inc. Low profile adaptor for use with a medical catheter
US20040044330A1 (en) * 2002-02-19 2004-03-04 Changqing Li Medical catheter assembly including multi-piece connector
US20040122438A1 (en) * 2002-12-23 2004-06-24 Boston Scientific Corporation Flex-tight interlocking connection tubing for delivery of bone cements/biomaterials for vertebroplasty
US20040225254A1 (en) * 2003-05-07 2004-11-11 Don Tanaka Localized pleurodesis chemical delivery
US7828789B2 (en) 2003-05-07 2010-11-09 Portaero, Inc. Device and method for creating a localized pleurodesis and treating a lung through the localized pleurodesis
US8029492B2 (en) 2003-05-07 2011-10-04 Portaero, Inc. Method for treating chronic obstructive pulmonary disease
US7811274B2 (en) 2003-05-07 2010-10-12 Portaero, Inc. Method for treating chronic obstructive pulmonary disease
US20080188824A1 (en) * 2003-05-07 2008-08-07 Portaero, Inc. Implantable device and method for creating a localized pleurodesis and treating a lung through the localized pleurodesis
US20080188809A1 (en) * 2003-05-07 2008-08-07 Portaero, Inc. Device and method for creating a localized pleurodesis and treating a lung through the localized pleurodesis
JP2004358241A (en) * 2003-05-20 2004-12-24 Cordis Corp Intra/extra-thoracic collateral ventilation bypass system
US20040231674A1 (en) * 2003-05-20 2004-11-25 Don Tanaka Intra/extra-thoracic collateral ventilation bypass system
EP1481650A3 (en) * 2003-05-20 2006-04-26 Cordis Corporation Intra/extra-thoracic collateral ventilation bypass system
US7789083B2 (en) 2003-05-20 2010-09-07 Portaero, Inc. Intra/extra thoracic system for ameliorating a symptom of chronic obstructive pulmonary disease
US7426929B2 (en) 2003-05-20 2008-09-23 Portaero, Inc. Intra/extra-thoracic collateral ventilation bypass system and method
US20040237966A1 (en) * 2003-05-29 2004-12-02 Don Tanaka Methods and devices to assist pulmonary decompression
US7533667B2 (en) 2003-05-29 2009-05-19 Portaero, Inc. Methods and devices to assist pulmonary decompression
US7896008B2 (en) 2003-06-03 2011-03-01 Portaero, Inc. Lung reduction system
US20070270776A1 (en) * 2003-06-03 2007-11-22 Respira, Inc. Lung reduction system
US7377278B2 (en) 2003-06-05 2008-05-27 Portaero, Inc. Intra-thoracic collateral ventilation bypass system and method
US20040244803A1 (en) * 2003-06-05 2004-12-09 Don Tanaka Intra-thoracic collateral ventilation bypass system
US7753052B2 (en) 2003-06-05 2010-07-13 Portaero, Inc. Intra-thoracic collateral ventilation bypass system
US8323230B2 (en) 2003-07-15 2012-12-04 Portaero, Inc. Methods and devices to accelerate wound healing in thoracic anastomosis applications
US20100129420A1 (en) * 2003-07-15 2010-05-27 Portaero, Inc. Methods and devices to accelerate wound healing in thoracic anastomosis applications
US7682332B2 (en) 2003-07-15 2010-03-23 Portaero, Inc. Methods to accelerate wound healing in thoracic anastomosis applications
US20050025816A1 (en) * 2003-07-15 2005-02-03 Don Tanaka Methods and devices to accelerate wound healing in thoracic anastomosis applications
US20060118126A1 (en) * 2004-11-19 2006-06-08 Don Tanaka Methods and devices for controlling collateral ventilation
US7398782B2 (en) 2004-11-19 2008-07-15 Portaero, Inc. Method for pulmonary drug delivery
US20060107961A1 (en) * 2004-11-19 2006-05-25 Don Tanaka Localized pleurodesis evacuation device
US20060118125A1 (en) * 2004-11-19 2006-06-08 Don Tanaka Pulmonary drug delivery
US8220460B2 (en) 2004-11-19 2012-07-17 Portaero, Inc. Evacuation device and method for creating a localized pleurodesis
US20060124126A1 (en) * 2004-12-10 2006-06-15 Don Tanaka Collateral ventilation device with chest tube/evacuation features
US7824366B2 (en) 2004-12-10 2010-11-02 Portaero, Inc. Collateral ventilation device with chest tube/evacuation features and method
US8104474B2 (en) 2005-08-23 2012-01-31 Portaero, Inc. Collateral ventilation bypass system with retention features
US20070051372A1 (en) * 2005-08-23 2007-03-08 Don Tanaka Collateral ventilation bypass system with retention features
US7686013B2 (en) 2006-01-17 2010-03-30 Portaero, Inc. Variable resistance pulmonary ventilation bypass valve
US7406963B2 (en) 2006-01-17 2008-08-05 Portaero, Inc. Variable resistance pulmonary ventilation bypass valve and method
US7726305B2 (en) 2006-01-17 2010-06-01 Portaero, Inc. Variable resistance pulmonary ventilation bypass valve
US20070163598A1 (en) * 2006-01-17 2007-07-19 Asia Chang Variable resistance pulmonary ventilation bypass valve
US20080281295A1 (en) * 2007-05-11 2008-11-13 Portaero, Inc. Visceral pleura ring connector
US8163034B2 (en) 2007-05-11 2012-04-24 Portaero, Inc. Methods and devices to create a chemically and/or mechanically localized pleurodesis
US20080281151A1 (en) * 2007-05-11 2008-11-13 Portaero, Inc. Pulmonary pleural stabilizer
US7931641B2 (en) 2007-05-11 2011-04-26 Portaero, Inc. Visceral pleura ring connector
US20080281433A1 (en) * 2007-05-11 2008-11-13 Portaero, Inc. Methods and devices to create a chemically and/or mechanically localized pleurodesis
US20100147294A1 (en) * 2007-05-15 2010-06-17 Portaero, Inc. Devices and methods to maintain the patency of an opening relative to parenchymal tissue of the lung
US20100147295A1 (en) * 2007-05-15 2010-06-17 Portaero, Inc. Devices and methods to create and maintain the patency of an opening relative to parenchymal tissue of the lung
US20080283065A1 (en) * 2007-05-15 2008-11-20 Portaero, Inc. Methods and devices to maintain patency of a lumen in parenchymal tissue of the lung
US20080287878A1 (en) * 2007-05-15 2008-11-20 Portaero, Inc. Pulmonary visceral pleura anastomosis reinforcement
US8062315B2 (en) * 2007-05-17 2011-11-22 Portaero, Inc. Variable parietal/visceral pleural coupling
US20080295829A1 (en) * 2007-05-30 2008-12-04 Portaero, Inc. Bridge element for lung implant
US20090192469A1 (en) * 2008-01-24 2009-07-30 Istvan Bognar Devices and Methods for Development of a Scar Tissue Tunnel Track
US20090209856A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US8231581B2 (en) 2008-02-19 2012-07-31 Portaero, Inc. Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US8491602B2 (en) 2008-02-19 2013-07-23 Portaero, Inc. Single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US20090205648A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management system with secretion management features for treatment of chronic obstructive pulmonary disease
US20100286544A1 (en) * 2008-02-19 2010-11-11 Portaero, Inc. Methods and devices for assessment of pneumostoma function
US20090205651A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. One-piece pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US7909803B2 (en) 2008-02-19 2011-03-22 Portaero, Inc. Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US7927324B2 (en) 2008-02-19 2011-04-19 Portaero, Inc. Aspirator and method for pneumostoma management
US20090205643A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Accelerated two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US20110118669A1 (en) * 2008-02-19 2011-05-19 Portaero, Inc. Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US20090205645A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management method for the treatment of chronic obstructive pulmonary disease
US8475389B2 (en) 2008-02-19 2013-07-02 Portaero, Inc. Methods and devices for assessment of pneumostoma function
US8021320B2 (en) 2008-02-19 2011-09-20 Portaero, Inc. Self-sealing device and method for delivery of a therapeutic agent through a pneumostoma
US20090209924A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Enhanced pneumostoma management device and methods for treatment of chronic obstructive pulmonary disease
US20090205641A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease
US20090205649A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Multi-layer pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US20090209936A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Aspirator and method for pneumostoma management
US20090209909A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Percutaneous single-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US20090205646A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US8506577B2 (en) 2008-02-19 2013-08-13 Portaero, Inc. Two-phase surgical procedure for creating a pneumostoma to treat chronic obstructive pulmonary disease
US8252003B2 (en) 2008-02-19 2012-08-28 Portaero, Inc. Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US20090209971A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US20090205644A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Pneumostoma management system for treatment of chronic obstructive pulmonary disease
US20090205650A1 (en) * 2008-02-19 2009-08-20 Portaero, Inc. Variable length pneumostoma management system for treatment of chronic obstructive pulmonary disease
US8336540B2 (en) 2008-02-19 2012-12-25 Portaero, Inc. Pneumostoma management device and method for treatment of chronic obstructive pulmonary disease
US8474449B2 (en) 2008-02-19 2013-07-02 Portaero, Inc. Variable length pneumostoma management system for treatment of chronic obstructive pulmonary disease
US8347880B2 (en) 2008-02-19 2013-01-08 Potaero, Inc. Pneumostoma management system with secretion management features for treatment of chronic obstructive pulmonary disease
US8464708B2 (en) 2008-02-19 2013-06-18 Portaero, Inc. Pneumostoma management system having a cosmetic and/or protective cover
US8348906B2 (en) 2008-02-19 2013-01-08 Portaero, Inc. Aspirator for pneumostoma management
US8365722B2 (en) 2008-02-19 2013-02-05 Portaero, Inc. Multi-layer pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US8430094B2 (en) 2008-02-19 2013-04-30 Portaero, Inc. Flexible pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US8453637B2 (en) 2008-02-19 2013-06-04 Portaero, Inc. Pneumostoma management system for treatment of chronic obstructive pulmonary disease
US8453638B2 (en) 2008-02-19 2013-06-04 Portaero, Inc. One-piece pneumostoma management system and methods for treatment of chronic obstructive pulmonary disease
US8347881B2 (en) 2009-01-08 2013-01-08 Portaero, Inc. Pneumostoma management device with integrated patency sensor and method
US20100170507A1 (en) * 2009-01-08 2010-07-08 Portaero, Inc. Pneumostoma management device with integrated patency sensor and method
US8518053B2 (en) 2009-02-11 2013-08-27 Portaero, Inc. Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US20100204707A1 (en) * 2009-02-11 2010-08-12 Portaero, Inc. Surgical instruments for creating a pneumostoma and treating chronic obstructive pulmonary disease
US20110152774A1 (en) * 2009-12-23 2011-06-23 Jose Luis Lopez Ophthalmic valved trocar cannula
US8343106B2 (en) 2009-12-23 2013-01-01 Alcon Research, Ltd. Ophthalmic valved trocar vent
US8679064B2 (en) 2009-12-23 2014-03-25 Alcon Research, Ltd. Ophthalmic valved trocar cannula
US8277418B2 (en) 2009-12-23 2012-10-02 Alcon Research, Ltd. Ophthalmic valved trocar cannula
US20110152775A1 (en) * 2009-12-23 2011-06-23 Jose Luis Lopez Ophthalmic valved trocar vent

Similar Documents

Publication Publication Date Title
US3638649A (en) Implantable prosthetic pass-through device
US4086665A (en) Artificial blood conduit
US3853126A (en) Artery-to-vein shunt
US5807356A (en) Catheter with valve
CA1092927A (en) Hemodialysis cannula for subclavian insertion
US3818511A (en) Medical prosthesis for ducts or conduits
US4676782A (en) Positionable tissue interfacing device for the management of percutaneous conduits
US4790810A (en) Ureteral connector stent
US8177770B2 (en) Catheter connector system
US4278092A (en) Peritoneal catheter
JP3285584B2 (en) Prostheses for treatment of natural lumens or vessels, such as prostheses in the urethra
US3826257A (en) Prosthetic shunt
US20130274648A1 (en) Blood flow controllers and methods
US20090234431A1 (en) Arteriovenous graft blood flow controllers and methods
Sparks Silicone mandril method of femoropopliteal artery bypass: Clinical experience and surgical technics
EP2609892B1 (en) Ureteral stent
US20130226094A1 (en) Introducer assembly
GB2105197A (en) Body implantable connector for connection to an implant device
US4484912A (en) Atraumatic blood access device sealing mechanism
US4240794A (en) Method of preforming vascular grafts of human and other animal origin
CN203425299U (en) Embedded blood drainage tube for hematodialysis
RU183498U1 (en) Artery wall defect closure
CN208017520U (en) A kind of temporary vascular shunt device
CN216934413U (en) Medical guide wire locking device
CN216571147U (en) Balloon catheter

Legal Events

Date Code Title Description
AS Assignment

Owner name: NEUROMEDICS, INC., A CORP. OF TX, TEXAS

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MED GENERAL, INC.,;REEL/FRAME:003834/0020

Effective date: 19801229

Owner name: NEUROMEDICS, INC., A CORP. OF TX

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:MED GENERAL, INC.,;REEL/FRAME:003834/0020

Effective date: 19801229

AS Assignment

Owner name: BRAZOSPORT BANK OF TEXAS

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC.;AND OTHERS;REEL/FRAME:004303/0077

Effective date: 19840726

Owner name: FIRST FREEPORT NATIONAL BANK

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC.;AND OTHERS;REEL/FRAME:004303/0077

Effective date: 19840726

Owner name: TRUST COMPANY BANK

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC.;AND OTHERS;REEL/FRAME:004303/0077

Effective date: 19840726

Owner name: FIRST NATIONAL BANK OF CHICAGO, THE

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC.;AND OTHERS;REEL/FRAME:004303/0077

Effective date: 19840726

Owner name: CHASE MANHATTAN BANK, N.A., THE

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC.;AND OTHERS;REEL/FRAME:004303/0077

Effective date: 19840726

Owner name: BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIA

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC.;AND OTHERS;REEL/FRAME:004303/0077

Effective date: 19840726

Owner name: CITIBANK, N.A., AS AGENT

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC.;AND OTHERS;REEL/FRAME:004303/0077

Effective date: 19840726

AS Assignment

Owner name: CITICORP MILTILEASE (SEF), INC.

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC.;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC., A CORP. OF TEXAS;AND OTHERS;REEL/FRAME:004452/0900

Effective date: 19850703

Owner name: CHASE COMMERCIAL CORPORATION

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC., A CORP. OF TEXAS;INTERMEDICS CARDIASSIST, INC., A CORP OF TX.;INTERMEDICS INTRAOCULAR, INC., A CORP. OF TEXAS;AND OTHERS;REEL/FRAME:004449/0501

Effective date: 19850703

Owner name: B.A. LEASING CORPORATION

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC., A CORP. OF TEXAS;INTERMEDICS CARDIASSIST, INC.;INTERMEDICS INTRAOCULAR, INC., A CORP. OF TEXAS;AND OTHERS;REEL/FRAME:004449/0424

Effective date: 19850703

Owner name: CITIBANK, N.A.

Free format text: SECURITY INTEREST;ASSIGNORS:INTERMEDICS, INC., A TX CORP;INTERMEDICS CARDIASSIST, INC., A TX CORP.;INTERMEDICS INTRAOCULAR, INC., A TX CORP.;AND OTHERS;REEL/FRAME:004434/0728

Effective date: 19850703

AS Assignment

Owner name: INTERMEDICS, INC., INTERMEDICS CARDIASSIST, INC.,

Free format text: SAID PARTIES RECITES OBLIGATIONS RECITED IN SECURITY AGREEMENT RECORDED SEPTEMBER 17, 1984 REEL 4303 FRAMES 077-127 HAVE BEEN PAID IN FULL ALL;ASSIGNOR:CITIBANK, N.A., INDIVIDUALLY AND AS AGENT FOR BANK OF AMERICA NATIONAL TRUST AND SAVINGS ASSOCIATION, THE CHASE MANHATTAN BANK, N.A., THE FIRST NATIONAL BANK OF CHICAGO, TRUST COMPANY BANK, FIRST FREEPORT NATIONAL BANK OF BRAZOSPORT BANK OF TEXAS;REEL/FRAME:004592/0424

Effective date: 19860502

Owner name: INTERMEDICS, INC., INTERMEDICS CARDIASSIST, INC.,

Free format text: SECURED PARTY HEREBY RELEASE THE SECURITY INTEREST IN AGREEMENT RECORDED AUGUST 5, 1985. REEL 4434 FRAMES 728-782;ASSIGNOR:CITIBANK, N.A.;REEL/FRAME:004592/0394

Effective date: 19860502

Owner name: INTERMEDICS, INC.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CITICORP MULTILEASE (SEF), INC.;REEL/FRAME:004576/0516

Effective date: 19860515

AS Assignment

Owner name: CALCITEK, INC., A TEXAS CORP., STATELESS

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: NEUROMEDICS, INC., A TEXAS CORP., STATELESS

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: CARBOMEDICS, INC., A TEXAS CORP., STATELESS

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: SURGITRONICS CORPORATION, A TEXAS CORP., STATELESS

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: INTERMEDICS INTRAOCULAR, INC., A TEXAS CORP., STAT

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: INTERMEDICS CARDIASSIST, INC., A TEXAS CORP., STAT

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: INTERMEDICS, INC., A TEXAS CORP., STATELESS

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: AMERICAN PACEMAKER CORPORATION A CORP OF MA

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: CALCITEK, INC., ALL TEXAS CORPS

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: NEUROMEDICS, INC.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: CARBO-MEDICS, INC.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: SURGITRONICS CORPORATION

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: INTERMEDICS INTRAOCULAR, INC.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: INTERMEDICS CARDIASSIST, INC.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: INTERMEDICS, INC.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:CHASE COMMERCIAL CORPORATION;REEL/FRAME:004605/0581

Effective date: 19860804

Owner name: AMERICAN PACEMAKER CORPORATION, A MASSACHUSETTS CO

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: CALCITEK, INC., A TEXAS CORP.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: NEUROMEDICS, INC., A TEXAS CORP.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: CARBOMEDICS, INC., A TEXAS CORP.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: SURGITRONICS CORPORATION, A TEXAS CORP.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: INTERMEDICS INTRAOCULAR, INC., A TEXAS CORP.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: INTERMEDICS CARDIASSIST, INC., A TEXAS CORP.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813

Owner name: INTERMEDICS, INC., A TEXAS CORP.

Free format text: RELEASED BY SECURED PARTY;ASSIGNOR:B. A. LEASING CORPORATION;REEL/FRAME:004603/0607

Effective date: 19860813